Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Jul;55(3):555-64.

Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor

Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor

G Doekes et al. Immunology. 1985 Jul.

Abstract

The influence of IgM-rheumatoid factor (IgM-RF) on the activation of isolated C1 by soluble IgG aggregates (AIgG) and immune complexes was studied. IgM preparations obtained from the sera of four patients with seropositive rheumatoid arthritis markedly reduced the C1 activation capacity of AIgG, especially when large aggregates were tested. The results of parallel experiments with radiolabelled AIgG indicated that this inhibitory effect of IgM-RF was accompanied by a very large increase of the aggregate size. A comparable IgM preparation isolated from pooled normal human serum influenced neither the size nor the C1 activation capacity of AIgG. The inhibitory effect of IgM-RF on C1 activation was also demonstrated for soluble tetanus-anti-tetanus immune complexes. Thus, in spite of the established C activation ability of IgM-RF and the fact that, in general, larger IgG aggregates and immune complexes activate C1 more efficiently, cross-linking and size enlargement of soluble IgG complexes and aggregates by IgM-RF lead to a decrease of the C1 activation capacity. As a consequence, IgM-RF may reduce plasma complement activation by soluble IgG complexes in the circulation of patients with seropositive rheumatic diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arthritis Rheum. 1968 Aug;11(4):523-36 - PubMed
    1. J Immunol. 1970 Nov;105(5):1206-14 - PubMed
    1. Arthritis Rheum. 1970 Nov-Dec;13(6):713-23 - PubMed
    1. J Exp Med. 1970 Oct 1;132(4):673-93 - PubMed
    1. Immunochemistry. 1971 Jul;8(7):593-602 - PubMed

Publication types

MeSH terms

LinkOut - more resources